Integrated eQTL-pQTL Mendelian randomization and single-cell sequencing reveal therapeutic targets in ovarian clear cell cancer
- PMID: 40593373
- PMCID: PMC12214076
- DOI: 10.1007/s12672-025-03043-8
Integrated eQTL-pQTL Mendelian randomization and single-cell sequencing reveal therapeutic targets in ovarian clear cell cancer
Abstract
Background: Ovarian clear cell cancer (OCCC) is a pathological type of ovarian cancer. OCCC responds poorly to platinum-based chemotherapy drugs and immunotherapy. Currently, there is a lack of targeted drugs for OCCC. It is very urgent to find new therapeutic targets for OCCC.
Methods: We used data from the eQTLGen consortium and deCODE, combined with large Genome-Wide Association Study (GWAS) cohort data, to perform drug target Mendelian randomization (MR) analysis. Colocalization analysis was used to identify target genes. Then, we analyzed single-cell sequencing data from the GEO database, combing with gene enrichment analysis to explore possible molecular mechanisms. Drug screening and molecular docking verified the medicinal value of the targets.
Results: Three genes were selected in the MR analysis. Colocalization supported two of them, PPP1R14A and PTGS2. Single-cell sequencing analysis showed that these genes were related to tumor immunity. Drug prediction and molecular docking showed that PTGS2 had druggable potential.
Conclusions: This study identified two potential drug targets for OCCC. These drug targets may be relevant to tumor immunotherapy. However, further studies are necessary to confirm these findings and clarify the underlying mechanisms.
Keywords: Cancer immunotherapy; Mendelian randomization; Ovarian clear cell cancer; Single-cell RNA sequencing; Therapeutic targets.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Clinical trial number: Not applicable.
Figures









References
-
- Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239–57. 10.1038/s43018-023-00617-9. - PubMed
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. 10.3322/caac.21834. - PubMed
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. 10.3322/caac.21708. - PubMed
-
- Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 2023. 10.1016/j.canlet.2023.216057. - PubMed
-
- Iida Y, Okamoto A, Hollis RL, Gourley C, Herrington CS. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int J Gynecol Cancer. 2021;31(4):605–16. 10.1136/ijgc-2020-001656. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials